Medivir's Oncology Asset Purchase Seals TetraLogic's Death

Medivir, which recently reinvented itself as a solely oncology-based R&D company, is buying two programs for TetraLogic which will subsequently 'terminate all remaining employees'.

Crime scene

TetraLogic Pharmaceuticals Corp., whose shares have been in freefall since the start of the year, is selling its SMAC mimetic program, including its clinical-stage asset birinapant, and its topical HDAC inhibitor, SHAPE (also known as remetinostat), to Medivir AB.

Medivir will pay $12m in cash as well as future milestones of up to $153m based on the development and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip